Bayer eyes wider Nubeqa use on new prostate cancer trial data

[July 17, 2024]  By Ludwig Burger

FRANKFURT (Reuters) -Bayer said on Wednesday its Nubeqa drug was shown to slow the progression of a certain type of prostate cancer in a late-stage trial, underpinning growth prospects for one of the German drugmaker's key pharmaceutical products.

Bayer is developing Nubeqa, also known as darolutamide, jointly with Finland's Orion. The drug is already approved in other prostate cancer treatment settings.

Bayer said in a statement that Nubeqa, when combined with androgen deprivation therapy, significantly prolonged progression-free survival when compared with androgen deprivation therapy alone in a phase III trail.

Trial participants suffered from a type of metastatic prostate cancer that responds to hormone therapy.

Details of the trial would be presented at an as yet undisclosed medical conference, Bayer said, adding that it plans to seek regulatory approval for wider use of the drug.

The 120-metre-high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical industry in Leverkusen, Germany, September 23, 2023. REUTERS/Wolfgang Rattay/File Photo

(Reporting by Ludwig Burger, Editing by Rachel More)

[© 2024 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.